Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
Castle Biosciences (CSTL) presented new data at ACG 2024 showing their TissueCypher® test can significantly reduce healthcare costs and improve quality of life for Barrett's esophagus (BE) patients. Using a simulation model of 10,000 patients, the study demonstrated a $17M decrease in BE management costs when patients identified by TissueCypher as high-risk received endoscopic eradication therapy. The test reduced esophageal cancer progression by 58.4% and EAC-related death by 59.6%. The abstract received a Presidential Poster Award, an honor given to only 5-7% of submissions for outstanding research.
Castle Biosciences (CSTL) ha presentato nuovi dati all'ACG 2024 mostrando che il loro test TissueCypher® può ridurre significativamente i costi sanitari e migliorare la qualità della vita per i pazienti con esofago di Barrett (BE). Utilizzando un modello di simulazione di 10.000 pazienti, lo studio ha dimostrato una riduzione dei costi di gestione del BE di 17 milioni di dollari quando i pazienti identificati da TissueCypher come ad alto rischio hanno ricevuto terapia di eradicazione endoscopica. Il test ha ridotto la progressione del cancro esofageo del 58,4% e la mortalità legata all'EAC del 59,6%. L'abstract ha ricevuto un Premio Poster Presidenziale, un onore riservato solo al 5-7% delle presentazioni per la ricerca straordinaria.
Castle Biosciences (CSTL) presentó nuevos datos en el ACG 2024 mostrando que su prueba TissueCypher® puede reducir significativamente los costos de atención médica y mejorar la calidad de vida de los pacientes con esófago de Barrett (BE). Utilizando un modelo de simulación de 10,000 pacientes, el estudio demostró una reducción de costos de 17 millones de dólares en la gestión del BE cuando los pacientes identificados por TissueCypher como de alto riesgo recibieron terapia de erradicación endoscópica. La prueba redujo la progresión del cáncer esofágico en un 58.4% y la muerte relacionada con EAC en un 59.6%. El resumen recibió un Premio de Póster Presidencial, un honor otorgado solo al 5-7% de las presentaciones por investigaciones destacadas.
Castle Biosciences (CSTL)은 ACG 2024에서 그들의 TissueCypher® 테스트가 Barrett 식도환자 (BE)의 의료비를 크게 줄이고 삶의 질을 향상시킬 수 있음을 보여주는 새로운 데이터를 발표했습니다. 10,000명의 환자를 대상으로 한 시뮬레이션 모델을 사용하여 연구 결과, TissueCypher로 고위험군으로 분류된 환자가 내시경 제거 요법을 받을 때 BE 관리 비용이 1,700만 달러 감소하는 것으로 나타났습니다. 이 테스트는 식도암 진행률을 58.4% 줄였고 EAC 관련 사망률을 59.6% 감소시켰습니다. 이 초록은 뛰어난 연구로 대통령 포스터상을 수상했으며, 이는 제출물의 5-7%에게만 주어지는 영예입니다.
Castle Biosciences (CSTL) a présenté de nouvelles données lors de l'ACG 2024 montrant que leur test TissueCypher® peut réduire considérablement les coûts de santé et améliorer la qualité de vie des patients souffrant d'un œsophage de Barrett (BE). En utilisant un modèle de simulation de 10 000 patients, l'étude a démontré une réduction des coûts de gestion du BE de 17 millions de dollars lorsque les patients identifiés par TissueCypher comme étant à haut risque ont reçu une thérapie d'éradication endoscopique. Le test a réduit la progression du cancer de l'œsophage de 58,4% et la mortalité liée à l'EAC de 59,6%. L'abstract a reçu un Prix de Panneau Présidentiel, une distinction attribuée à seulement 5-7 % des soumissions pour des recherches exceptionnelles.
Castle Biosciences (CSTL) hat auf dem ACG 2024 neue Daten präsentiert, die zeigen, dass ihr TissueCypher®-Test die Gesundheitskosten erheblich senken und die Lebensqualität von Patienten mit Barrett-Ösophagus (BE) verbessern kann. Mithilfe eines Simulationsmodells mit 10.000 Patienten zeigte die Studie eine Reduktion der BE-Managementkosten um 17 Millionen US-Dollar, wenn Patienten, die von TissueCypher als hochriskant identifiziert wurden, eine endoskopische Eliminierungstherapie erhielten. Der Test reduzierte das Fortschreiten von Speiseröhrenkrebs um 58,4% und die EAC-bedingte Sterblichkeit um 59,6%. Der Abstract erhielt einen Presidential Poster Award, eine Auszeichnung, die nur 5-7% der Einreichungen für herausragende Forschung verliehen wird.
- Demonstrated $17M reduction in Barrett's esophagus management costs
- 58.4% reduction in esophageal cancer progression
- 59.6% reduction in EAC-related deaths
- Received prestigious Presidential Poster Award (top 5-7% of submissions)
- None.
Insights
The study demonstrates compelling clinical and economic benefits of the TissueCypher test in Barrett's esophagus (BE) management. The
The test's ability to stratify patients into risk categories enables precision medicine: low-risk patients avoid unnecessary procedures while high-risk patients receive timely interventions. This dual approach optimizes resource allocation while improving outcomes. The Presidential Poster Award validates the research quality and potential market impact. For Castle Biosciences, this data strengthens the test's value proposition to healthcare payers and providers, potentially driving broader adoption and revenue growth.
This clinical validation strengthens Castle Biosciences' market position in the BE diagnostic space. With over 3.3 million BE patients in the U.S., the total addressable market is substantial. The demonstrated cost savings and improved outcomes provide compelling evidence for insurance coverage and clinical adoption. The prestigious award recognition at ACG 2024 adds credibility and visibility to the test.
The data showing both cost reduction and significant clinical benefits creates a strong value proposition for healthcare systems and payers. This could accelerate market penetration and boost test volumes, particularly as healthcare systems increasingly focus on cost-effective preventive care. The reduction in cancer progression rates could establish TissueCypher as a standard of care in BE management.
TissueCypher abstract awarded a Presidential Poster Award by ACG Abstract Selection Committee, a distinction awarded to only 5
“Our team from four different academic medical centers collaborated to evaluate the cost-effectiveness of TissueCypher in guiding surveillance and treatment of Barrett’s esophagus,” said Cadman L. Leggett, M.D., Division of Gastroenterology at Mayo Clinic in
More than 5,100 scientific abstracts will be presented during ACG 2024. Only a small percentage of these, including Castle’s TissueCypher poster, received a Presidential Poster Award, recognizing high quality, novel, unique or interesting research. Details regarding Castle’s award-winning poster are included below:
P3924. (S702). Risk-Aligned Management Guided by the Tissue Systems Pathology Test Can Improve Health Outcomes in Barrett’s Esophagus and Reduce Healthcare-Associated Costs
-
Key takeaways:
- This study evaluated the cost-effectiveness of TissueCypher-guided management for patients with BE.
- The data demonstrated that care guided by the test can significantly reduce patient management costs due to de-escalated care for patients with low-risk test results (e.g., reduced overutilization of surveillance and EET) and escalated care for patients with higher-risk test results (e.g., earlier use of EET to prevent development of high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC) and increased surveillance).
-
In addition to significant cost savings to the healthcare system, the study highlights how care guided by the TissueCypher test can improve patient quality of life and health outcomes, as well as contribute to a significant reduction in the incidence of HGD/EAC by
58.4% and EAC-related death by59.6% .
To view the full poster, visit the ACG 2024 ePoster Hall. To learn more about TissueCypher, visit Castle at booth 1083.
About TissueCypher® Barrett’s Esophagus Test
The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s esophagus (BE). The TissueCypher Barrett’s Esophagus test is indicated for use in patients with endoscopic biopsy-confirmed BE that is graded non-dysplastic (NDBE), indefinite for dysplasia (IND) or low-grade dysplasia (LGD); its clinical performance has been supported by 14 peer-reviewed publications of BE progressor patients with leading clinical centers around the world. The test received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS) in March 2022. Learn more at www.CastleBiosciences.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of the TissueCypher test to (i) significantly reduce healthcare management costs and improve the quality of life and health outcomes for patients with BE and (ii) contribute to a significant reduction in the incidence of HGD/EAC. The words “can,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results shown in this study, including with respect to the discussion of TissueCypher in this press release; actual application of our TissueCypher test may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029353348/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
How much did Castle Biosciences' TissueCypher test reduce healthcare costs for Barrett's esophagus management?
What was the reduction in cancer progression using Castle Biosciences' (CSTL) TissueCypher test?
What recognition did Castle Biosciences' TissueCypher study receive at ACG 2024?
